Literature DB >> 15920133

Angiotensin receptor blockers and myocardial infarction: results reflect different cardiovascular states in patients with types 1 and 2 diabetes.

Edmund J Lewis.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15920133      PMCID: PMC558133          DOI: 10.1136/bmj.330.7502.1269-a

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  5 in total

1.  Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

Authors:  E J Lewis; L G Hunsicker; W R Clarke; T Berl; M A Pohl; J B Lewis; E Ritz; R C Atkins; R Rohde; I Raz
Journal:  N Engl J Med       Date:  2001-09-20       Impact factor: 91.245

2.  Angiotensin receptor blockers and myocardial infarction.

Authors:  Subodh Verma; Marty Strauss
Journal:  BMJ       Date:  2004-11-27

3.  Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy.

Authors:  Tomas Berl; Lawrence G Hunsicker; Julia B Lewis; Marc A Pfeffer; Jerome G Porush; Jean-Lucien Rouleau; Paul L Drury; Enric Esmatjes; Donald Hricik; Chirag R Parikh; Itamar Raz; Philippe Vanhille; Thomas B Wiegmann; Bernard M Wolfe; Francesco Locatelli; Samuel Z Goldhaber; Edmund J Lewis
Journal:  Ann Intern Med       Date:  2003-04-01       Impact factor: 25.391

Review 4.  Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review.

Authors:  Giovanni F M Strippoli; Maria Craig; Jonathan J Deeks; Francesco Paolo Schena; Jonathan C Craig
Journal:  BMJ       Date:  2004-09-30

5.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

Authors:  E J Lewis; L G Hunsicker; R P Bain; R D Rohde
Journal:  N Engl J Med       Date:  1993-11-11       Impact factor: 91.245

  5 in total
  1 in total

Review 1.  A current evaluation of the safety of angiotensin receptor blockers and direct renin inhibitors.

Authors:  Helmy M Siragy
Journal:  Vasc Health Risk Manag       Date:  2011-05-19
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.